A new treatment for ovarian cancer that extends patients’ lives and reduces side effects is now available on the NHS in England but is not accessible in Sweden, according to reports. The drug, mirvetuximab soravtansine, targets cancerous cells more precisely than traditional chemotherapy, minimizing systemic toxicity.
How the Treatment Works
Mirvetuximab soravtansine, described as a “biological missile,” delivers chemotherapy directly to cancerous tissue rather than the entire body. This targeted approach reduces common side effects such as hair loss and severe fatigue, allowing patients to maintain a better quality of life. The drug is administered via intravenous drip every three weeks, compared to weekly sessions for conventional chemotherapy.
Impact on Patients
Patricia Hill, a 64-year-old patient from north London, reported significant improvements after starting the treatment in January. She described the drug as a “game changer,” enabling her to attend theater performances, visit family, and participate in social activities that were previously impossible with standard chemotherapy. The
